Checkpoint Therapeutics I... (CKPT)
Checkpoint Therapeutics Statistics
Share Statistics
Checkpoint Therapeutics has 48.13M shares outstanding. The number of shares has increased by 110.87% in one year.
| Shares Outstanding | 48.13M |
| Shares Change (YoY) | 110.87% |
| Shares Change (QoQ) | 8.61% |
| Owned by Institutions (%) | 5.63% |
| Shares Floating | 35.94M |
| Failed to Deliver (FTD) Shares | 231 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 5.56M, so 11.56% of the outstanding shares have been sold short.
| Short Interest | 5.56M |
| Short % of Shares Out | 11.56% |
| Short % of Float | 14.7% |
| Short Ratio (days to cover) | 5.7 |
Valuation Ratios
The PE ratio is -0.83 and the forward PE ratio is 10.7. Checkpoint Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.83 |
| Forward PE | 10.7 |
| PS Ratio | 416.7 |
| Forward PS | 0.4 |
| PB Ratio | -3.29 |
| P/FCF Ratio | -0.9 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Checkpoint Therapeutics Inc. has an Enterprise Value (EV) of 37.99M.
| EV / Earnings | -0.73 |
| EV / Sales | 368.86 |
| EV / EBITDA | -0.73 |
| EV / EBIT | -0.73 |
| EV / FCF | -0.8 |
Financial Position
The company has a current ratio of 0.29, with a Debt / Equity ratio of 0.
| Current Ratio | 0.29 |
| Quick Ratio | 0.29 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 3.97% and return on capital (ROIC) is 399.69%.
| Return on Equity (ROE) | 3.97% |
| Return on Assets (ROA) | -9.64% |
| Return on Capital (ROIC) | 399.69% |
| Revenue Per Employee | $4,478.26 |
| Profits Per Employee | $-2,254,217.39 |
| Employee Count | 23 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 27.8% in the last 52 weeks. The beta is 1.36, so Checkpoint Therapeutics's price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | 27.8% |
| 50-Day Moving Average | 3.23 |
| 200-Day Moving Average | 2.75 |
| Relative Strength Index (RSI) | 41.8 |
| Average Volume (20 Days) | 1.31M |
Income Statement
In the last 12 months, Checkpoint Therapeutics had revenue of 103K and earned -51.85M in profits. Earnings per share was -2.77.
| Revenue | 103K |
| Gross Profit | -43.46M |
| Operating Income | -52.15M |
| Net Income | -51.85M |
| EBITDA | -52.15M |
| EBIT | -52.15M |
| Earnings Per Share (EPS) | -2.77 |
Balance Sheet
The company has 4.93M in cash and 0 in debt, giving a net cash position of 4.93M.
| Cash & Cash Equivalents | 4.93M |
| Total Debt | 0 |
| Net Cash | 4.93M |
| Retained Earnings | -314.33M |
| Total Assets | 5.18M |
| Working Capital | -12.59M |
Cash Flow
In the last 12 months, operating cash flow was -47.59M and capital expenditures 0, giving a free cash flow of -47.59M.
| Operating Cash Flow | -47.59M |
| Capital Expenditures | 0 |
| Free Cash Flow | -47.59M |
| FCF Per Share | -2.54 |
Margins
Gross margin is -42.2K%, with operating and profit margins of -50.63K% and -50.34K%.
| Gross Margin | -42.2K% |
| Operating Margin | -50.63K% |
| Pretax Margin | -50.34K% |
| Profit Margin | -50.34K% |
| EBITDA Margin | -50.63K% |
| EBIT Margin | -50.63K% |
| FCF Margin | -46.2K% |
Dividends & Yields
CKPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -97.19% |
| FCF Yield | -34.63% |
Analyst Forecast
The average price target for CKPT is $9, which is 215.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 215.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Dec 6, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 6, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -114.68 |
| Piotroski F-Score | 3 |